News Desk
The GLP1 Clinics News Desk covers breaking developments in the GLP-1 medication space, including regulatory changes, new clinical data, manufacturer announcements, and policy updates that impact patient access to weight loss treatments.
New JAMA Surgery study reveals dramatic shift in obesity treatment as GLP-1 prescriptions more than double while bariatric surgeries fall to lowest levels since 2020.
FDA approved 7.2mg semaglutide injection in record 54 days, delivering 20.7% average weight loss - the most effective obesity treatment ever approved.
Cleveland Clinic study of 10,000+ cancer patients shows GLP-1 drugs like Wegovy and Zepbound reduced risk of metastatic progression by up to 45%, especially in breast cancer.
